The clinical study was based on tests conducted on 68 patients in a hospital in Malawi between February and March this year. It showed that BiliSpec has ”comparable accuracy to the more expensive laboratory tests found in high-resource settings.” Pelham Keahey, co-author of the study, says the next step is  “a larger, two-year follow-up study of efficacy and usability.” The study will now be expanded to five hospitals in Malawi as the team chases its goal of reducing the number of newborn deaths in African hospitals by half within 10 years. The team has already raised $750,000 in funding as it pushes to develop “a commercial-ready device.”

In general, jaundice can affect “up to 60% of full term babies” but newborns in Africa are 100 times more likely to die from jaundice than babies in the United States. As newborns typically do not have fully developed livers, their bodies are unable to process excess bilirubin, a substance created by the breakdown of red blood cells. A buildup of the substance in a newborn’s bloodstream results in yellow pigmentation of the skin. In cases where jaundice is detected, treatment can include phototherapy, blood transfusion or frequent feedings (this encourages frequent excretion which also helps remove bilirubin from the body). But if left untreated, it can result in brain damage and death.

📬 Sign up for the Daily Brief

Our free, fast, and fun briefing on the global economy, delivered every weekday morning.